Skip to content Skip to footer
Subscribe Now
NEWS

IntraGel Therapeutics and UroGen Pharma Ink Strategic Collaboration &  Investment to Advance TumoCure & Expand Sustained-Release Oncology Pipeline

Shots: IntraGel Therapeutics has entered into a strategic collaboration and investment agreement with UroGen Pharma to advance TumoCure for advanced head and neck cancer and expand the potential application of its SRGel biodegradable sustained-release platform As per the deal, UroGen will invest up to $7M in IntraGel to support the P-II development of TumoCure and…
6 hours ago

Read more

NEWS

IMPACT Therapeutics Inks Exclusive Licensing Agreement with Pharmanovia for Senaparib in EMEA, Australia and New Zealand

Shots: IMPACT Therapeutics has entered into an exclusive licensing agreement with Pharmanovia for the exclusive rights to manufacture, develop, and commercialise senaparib in EMEA, Australia, and New Zealand As per the deal, Pharmanovia will acquire exclusive rights to manufacture, develop & commercialise senaparib across EMEA, Australia & New Zealand, with IMPACT eligible for upfront, regulatory…
July 31, 2026

Read more